Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats

We have recently designed and synthesized several novel iminoquinone anticancer agents that have entered preclinical development for the treatment of human cancers. Herein we developed and validated a quantitative HPLC-MS/MS analytical method for one of the lead novel anticancer makaluvamine analog,...

Full description

Saved in:
Bibliographic Details
Published in:Chinese journal of natural medicines 2015-07, Vol.13 (7), p.554-560
Main Authors: YU, Jun-Xian, Voruganti, Sukesh, LI, Dan-Dan, Qin, Jiang-Jiang, Nag, Subhasree, Xu, Su, Velu, Sadanandan E., Wang, Wei, ZHANG, Ruiwen
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - blood
Antineoplastic Agents - pharmacokinetics
Chromatography, High Pressure Liquid - methods
LC-MS/MS
Makaluvamine analogs
Pharmacokinetics
Pyrroles - blood
Pyrroles - pharmacokinetics
Quinolones - blood
Quinolones - pharmacokinetics
Rat plasma
Rats, Sprague-Dawley
Tandem Mass Spectrometry - methods
TCBA-TPQ
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have recently designed and synthesized several novel iminoquinone anticancer agents that have entered preclinical development for the treatment of human cancers. Herein we developed and validated a quantitative HPLC-MS/MS analytical method for one of the lead novel anticancer makaluvamine analog, TCBA-TPQ, and conducted a pharmacokinetic study in laboratory rats. Our results indicated that the HPLC-MS/MS method was precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of TCBA-TPQ and plasma pharmacokinetics in rats. Our results provide a basis for future preclinical and clinical development of this promising anticancer marine analog.
ISSN:1875-5364
2095-6975
1875-5364
DOI:10.1016/S1875-5364(15)30051-0